New shot for hemophilia: patients share their experience

NCT ID NCT06992076

Recruiting now Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This registry follows 100 adults and teens with hemophilia A or B who are prescribed marstacimab, a once-weekly shot under the skin. The main goals are to see if patients prefer this shot over IV treatments and to measure treatment burden after 6 months. Researchers will also track bleeding rates and joint health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: marstacimab (a monoclonal antibody injection under the skin)
What this could lead to: If successful, this registry could show that a once-weekly shot is preferred over IV infusions and reduces bleeding episodes, improving quality of life for hemophilia patients.
What could go wrong: This is an observational registry, not a controlled trial, so results may not prove cause and effect. It is also small (100 participants) and focused on patient experience, not long-term safety or efficacy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophilia hemophilia A hemophilia B

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMOPHILIA

Contacts and locations

Locations

Institute of haematology and Blood diseases hospital
RECRUITING

Tianjin, Tianjin Municipality, China
The First Affiliated Hospital of Xiamen University
RECRUITING

Xiamen, Fujian, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.